{"title":"Quick fix or long-term cure? Pros and cons of bariatric surgery.","authors":"James A Madura, John K Dibaise","doi":"10.3410/M4-19","DOIUrl":"https://doi.org/10.3410/M4-19","url":null,"abstract":"<p><p>The past decade has seen an enormous increase in the number of bariatric, or weight loss, operations performed. This trend is likely to continue, mirroring the epidemic of obesity around the world and its rising prevalence among children. Bariatric surgery is considered by many to be the most effective treatment for obesity in terms of maintenance of long-term weight loss and improvement in obesity-related comorbid conditions. Although overly simplified, the primary mechanisms of the surgical interventions currently utilized to treat obesity are the creation of a restrictive or malabsorptive bowel anatomy. Operations based on these mechanisms include the laparoscopic adjustable gastric band and laparoscopic vertical sleeve gastrectomy (considered primarily restrictive operations), the laparoscopic biliopancreatic diversion with or without a duodenal switch (primarily malabsorptive operation), and the laparoscopic Roux-en-Y gastric bypass (considered a combination restrictive and selective malabsorptive procedure). Each operation has pros and cons. Important considerations, for the patient and surgeon alike, in the decision to proceed with bariatric surgery include the technical aspects of the operation, postoperative complications including long-term nutritional problems, magnitude of initial and sustained weight loss desired, and correction of obesity-related comorbidities. Herein, the pros and cons of the contemporary laparoscopic bariatric operations are reviewed and ongoing controversies relating to bariatric surgery are discussed: appropriate patient selection, appropriate operation selection for an individual patient, surgeon selection, and how to measure success after surgery.</p>","PeriodicalId":88480,"journal":{"name":"F1000 medicine reports","volume":"4 ","pages":"19"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3410/M4-19","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30996437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Brenda Auffinger, Bart Thaci, Pragati Nigam, Esther Rincon, Yu Cheng, Maciej S Lesniak
{"title":"New therapeutic approaches for malignant glioma: in search of the Rosetta stone.","authors":"Brenda Auffinger, Bart Thaci, Pragati Nigam, Esther Rincon, Yu Cheng, Maciej S Lesniak","doi":"10.3410/M4-18","DOIUrl":"10.3410/M4-18","url":null,"abstract":"<p><p>Malignant gliomas are heterogeneous, diffuse and highly infiltrating by nature. Despite wide surgical resection and improvements in radio- and chemotherapies, the prognosis of patients with glioblastoma multiforme remains extremely poor, with a median survival time of only 14.5 months from diagnosis to death. Particular challenges for glioblastoma multiforme therapy are posed by limitations in the extent of feasible surgical resections, distinct tumor heterogeneity, difficulties in drug delivery across the blood-brain barrier and low drug distribution within the tumor. Therefore, new paradigms permitting tumor-specific targeting and extensive intratumoral distribution must be developed to allow an efficient therapeutic delivery. This review highlights the latest advances in the treatment of glioblastoma multiforme and the recent developments that have resulted from the interchange between preclinical and clinical efforts. We also summarize and discuss novel therapies for malignant glioma, focusing on advances in the following main topics of glioblastoma multiforme therapy: immunotherapy, gene therapy, stem cell-based therapies and nanotechnology. We discuss strategies and outcomes of emerging therapeutic approaches in these fields, and the main challenges associated with the integration of discoveries that occur in the laboratory into clinical practice.</p>","PeriodicalId":88480,"journal":{"name":"F1000 medicine reports","volume":"4 ","pages":"18"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b1/3d/medrep-04-18.PMC3438652.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30917099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The CNS and bladder dysfunction.","authors":"Stasa D Tadic, Gert Holstege, Derek J Griffiths","doi":"10.3410/M4-20","DOIUrl":"https://doi.org/10.3410/M4-20","url":null,"abstract":"<p><p>The brain's role in the development and maintenance of bladder control is critical, although its precise role in patient-reported complaints such as urgency and urine leakage is unknown. Functional brain imaging studies have advanced our knowledge of brain activity during the micturition cycle, showing multiple neuronal circuits involved as parts of a 'brain-bladder control network.' Yet, new advances need to be made in order to incorporate this knowledge into existing models of neuroanatomy and of clinical syndromes of bladder dysfunction and related clinical practice. This short article explains why and how brain imaging methods are poised to achieve that goal and decode the role of the brain in widely prevalent clinical conditions related to bladder dysfunction.</p>","PeriodicalId":88480,"journal":{"name":"F1000 medicine reports","volume":"4 ","pages":"20"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3410/M4-20","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30996438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy.","authors":"Abhay Dhand, George Sakoulas","doi":"10.3410/M4-4","DOIUrl":"https://doi.org/10.3410/M4-4","url":null,"abstract":"<p><p>Methicillin-resistant S. aureus (MRSA) has emerged as the most common hospital-acquired pathogen and is associated with increased morbidity and mortality compared with other strains. Vancomycin has been the cornerstone of treatment of patients with serious MRSA infections for some decades and while more than 99% of clinical S. aureus isolates remain susceptible to vancomycin, we are beginning to see strains of MRSA with reduced susceptibility. This review discusses this phenomenon, the predictors of infection with such forms of MRSA, and current and future management options.</p>","PeriodicalId":88480,"journal":{"name":"F1000 medicine reports","volume":" ","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3410/M4-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39967975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Active surveillance for low-risk prostate cancer.","authors":"Laurence Klotz","doi":"10.3410/M4-16","DOIUrl":"10.3410/M4-16","url":null,"abstract":"<p><p>Active surveillance for localized prostate cancer entails initial expectant management rather than immediate therapy, with \"curative-intent\" treatment deferred until there is evidence that the patient is at increased risk for disease progression. This is a response to the clearly documented risks of over diagnosis and overtreatment of low-risk prostate cancer, which in most cases poses little or no threat to the patient. It is based upon the prolonged natural history of prostate cancer and is an attempt to balance the risks and side effects of overtreatment against the possibility of disease progression and a lost opportunity for cure. Low-risk prostate cancer is more accurately viewed as one of multiple risk factors for the presence of higher grade prostate cancer. Like atypical small acinar proliferation, (ASAP), it may be managed with close follow up but without radical intervention, unless there is clear evidence of more aggressive disease.</p>","PeriodicalId":88480,"journal":{"name":"F1000 medicine reports","volume":"4 ","pages":"16"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/08/c5/medrep-04-16.PMC3412317.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30833573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Advances in the diagnosis and treatment of acute pulmonary embolism.","authors":"Victor F Tapson","doi":"10.3410/M4-9","DOIUrl":"https://doi.org/10.3410/M4-9","url":null,"abstract":"<p><p>Over the past two decades, considerable progress in technology and clinical research methods have led to advances in the diagnosis, treatment and prevention of acute venous thromboembolism. Despite this, however, the diagnosis is still often missed and preventive methods are often ignored. Published guidelines are useful, but are limited by the existing evidence base so that controversies remain with regard to topics such as duration of anticoagulation, indications for placement and removal of inferior vena caval filters, and when and how to administer thrombolytic therapy. The morbidity and mortality of this disease remain high, particularly when undiagnosed. While preventive approaches remain crucial, the focus of this review is on the diagnostic and therapeutic approach to acute venous thromboembolism, with an emphasis on acute pulmonary embolism.</p>","PeriodicalId":88480,"journal":{"name":"F1000 medicine reports","volume":"4 ","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3410/M4-9","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30639101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Telomeres in disease.","authors":"Rodrigo Calado, Neal Young","doi":"10.3410/M4-8","DOIUrl":"https://doi.org/10.3410/M4-8","url":null,"abstract":"<p><p>Telomeres and telomere repair are basic molecular features of cells possessing linear DNA chromosomes and defects in them result in various diseases. This review examines recent advances in understanding these diseases, particularly at a molecular level, and in relating telomere dysfunction to clinical diseases. We also discuss the potential role of telomere elongation as a therapy in diseases, and more controversially, the prevention/reversal of aging.</p>","PeriodicalId":88480,"journal":{"name":"F1000 medicine reports","volume":"4 ","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/97/cf/medrep-04-08.PMC3318193.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30572847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cognitive behaviour therapy for schizophrenia.","authors":"Jean Addington, Tania Lecomte","doi":"10.3410/M4-6","DOIUrl":"10.3410/M4-6","url":null,"abstract":"<p><p>Schizophrenia is one of the major and potentially severe mental illnesses. Even with best practices, there are limitations to the effectiveness of treatments that include medications for this disorder. Relapse rates are high and often those with the illness remain symptomatic and functionally impaired. All the evidence suggests that individuals with schizophrenia do best with a combination of pharmacological and psychosocial intervention. One psychosocial treatment that has received much attention is cognitive behaviour therapy (CBT). This brief review will address what we know about the use and effectiveness of CBT at all phases of schizophrenia and its strengths, weaknesses and its future.</p>","PeriodicalId":88480,"journal":{"name":"F1000 medicine reports","volume":" ","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/31/68/medrep-04-06.PMC3292287.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40150683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Adrianne L Wong, Albert Hwa, Dov Hellman, Julia L Greenstein
{"title":"Surrogate insulin-producing cells.","authors":"Adrianne L Wong, Albert Hwa, Dov Hellman, Julia L Greenstein","doi":"10.3410/M4-15","DOIUrl":"10.3410/M4-15","url":null,"abstract":"<p><p>Diabetes, a large and growing worldwide health concern, affects the functional mass of the pancreatic beta cell, which in turn affects the glucose regulation of the body. Successful transplantation of cadaveric islets and pancreata for patients with uncontrolled type 1 diabetes has provided proof-of-concept for the development of commercial cell therapy approaches to treat diabetes. Three broad issues must be addressed before surrogate insulin-producing cells can become a reality: the development of a surrogate beta-cell source, immunoprotection, and translation. Cell therapy for diabetes is a real possibility, but many questions remain; through the collaborative efforts of multiple stakeholders this may become a reality.</p>","PeriodicalId":88480,"journal":{"name":"F1000 medicine reports","volume":"4 ","pages":"15"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/27/74/medrep-04-15.PMC3412316.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30833572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Is deep brain stimulation a prospective \"cure\" for addiction?","authors":"Wayne Hall, Adrian Carter","doi":"10.3410/M3-4","DOIUrl":"https://doi.org/10.3410/M3-4","url":null,"abstract":"Deep brain stimulation has been put forward as a potential “cure” for intractable drug addiction. This is largely based on preclinical studies in animal models of addiction and small case series of positive, but short-term, effects on addictive behaviour in highly selected individuals. The history of neurosurgical treatment for psychiatric disorders suggests that we should be cautious in prematurely advocating invasive neurosurgical procedures on the basis of such limited evidence. Further research is required in animal models of addiction and in people treated for other neurological or psychiatric disorders before trials in addicted populations can be justified.","PeriodicalId":88480,"journal":{"name":"F1000 medicine reports","volume":"3 ","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2011-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a3/9e/medrep-03-04.PMC3042315.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29737859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
